Preethi Krishnan

Summary

Publications

  1. Ng T, Pilot Matias T, Tripathi R, Schnell G, Krishnan P, Reisch T, et al. Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection. Viruses. 2018;10: pubmed publisher
  2. Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, et al. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445-54 pubmed publisher
    ..This study has been registered at ClinicalTrials.gov under registration number NCT01464827.). ..
  3. Krishnan P, Pilot Matias T, Schnell G, Tripathi R, Ng T, Reisch T, et al. Pooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials. Antimicrob Agents Chemother. 2018;62: pubmed publisher
    ..The glecaprevir/pibrentasvir regimen, when the recommended durations are used, allows for a pan-genotypic treatment option without the need for baseline resistance testing. ..
  4. Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, et al. Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir. Antimicrob Agents Chemother. 2016;60:1106-13 pubmed publisher
    ..Results from these analyses are informative in understanding the resistance profile of an ombitasvir- plus paritaprevir/ritonavir-based regimen in Japanese GT1b-infected patients. ..
  5. Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Dekhtyar T, et al. Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan. Antimicrob Agents Chemother. 2018;62: pubmed publisher
    ..The CERTAIN-1 and CERTAIN-2 studies have been registered at ClinicalTrials.gov under identifiers NCT02707952 and NCT02723084, respectively.). ..
  6. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979-87 pubmed publisher
    ..Study M12-116 is registered at ClinicalTrials.gov under registration no. NCT01181427.). ..